162 related articles for article (PubMed ID: 37161026)
1. MGMT is frequently inactivated in pancreatic NET-G2 and is associated with the therapeutic activity of STZ-based regimens.
Yagi K; Ono H; Kudo A; Kinowaki Y; Asano D; Watanabe S; Ishikawa Y; Ueda H; Akahoshi K; Tanaka S; Tanabe M
Sci Rep; 2023 May; 13(1):7535. PubMed ID: 37161026
[TBL] [Abstract][Full Text] [Related]
2. O
Watanabe H; Yamazaki Y; Fujishima F; Izumi K; Imamura M; Hijioka S; Toriyama K; Yatabe Y; Kudo A; Motoi F; Unno M; Sasano H
BMC Cancer; 2020 Dec; 20(1):1195. PubMed ID: 33287738
[TBL] [Abstract][Full Text] [Related]
3. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
[TBL] [Abstract][Full Text] [Related]
4. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
[TBL] [Abstract][Full Text] [Related]
5. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Raj N; Klimstra DS; Horvat N; Zhang L; Chou JF; Capanu M; Basturk O; Do RKG; Allen PJ; Reidy-Lagunes D
Pancreas; 2017 Jul; 46(6):758-763. PubMed ID: 28609363
[TBL] [Abstract][Full Text] [Related]
6. O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET).
Lemelin A; Barritault M; Hervieu V; Payen L; Péron J; Couvelard A; Cros J; Scoazec JY; Bin S; Villeneuve L; Lombard-Bohas C; Walter T;
Dig Liver Dis; 2019 Apr; 51(4):595-599. PubMed ID: 30824408
[TBL] [Abstract][Full Text] [Related]
7. Multiple Assays to Determine Methylguanine-Methyltransferase Status in Lung Carcinoids and Correlation with Clinical and Pathological Features.
Vatrano S; Giorcelli J; Votta A; Capone G; Izzo S; Gatti G; Righi L; Napoli F; Scagliotti G; Papotti M; Volante M; Rapa I
Neuroendocrinology; 2020; 110(1-2):1-9. PubMed ID: 31280263
[TBL] [Abstract][Full Text] [Related]
8. Critical appraisal of MGMT in digestive NET treated with alkylating agents.
de Mestier L; Couvelard A; Blazevic A; Hentic O; de Herder WW; Rebours V; Paradis V; Ruszniewski P; Hofland LJ; Cros J
Endocr Relat Cancer; 2020 Oct; 27(10):R391-R405. PubMed ID: 32698158
[TBL] [Abstract][Full Text] [Related]
9. Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?
Hiddinga B; Zwaenepoel K; Janssens A; Van Meerbeeck J; Pauwels P
Oncotarget; 2022; 13():800-809. PubMed ID: 35677534
[TBL] [Abstract][Full Text] [Related]
10. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Cros J; Hentic O; Rebours V; Zappa M; Gille N; Theou-Anton N; Vernerey D; Maire F; Lévy P; Bedossa P; Paradis V; Hammel P; Ruszniewski P; Couvelard A
Endocr Relat Cancer; 2016 Aug; 23(8):625-33. PubMed ID: 27353036
[TBL] [Abstract][Full Text] [Related]
11. Expression of O(6)-methylguanine DNA methyltransferase (MGMT) and its clinical significance in gastroenteropancreatic neuroendocrine neoplasm.
Yang QC; Wang YH; Lin Y; Xue L; Chen YJ; Chen MH; Chen J
Int J Clin Exp Pathol; 2014; 7(7):4204-12. PubMed ID: 25120800
[TBL] [Abstract][Full Text] [Related]
12. Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET.
Hijioka S; Sakuma K; Aoki M; Mizuno N; Kuwahara T; Okuno N; Hara K; Yatabe Y
Cancer Chemother Pharmacol; 2019 Jan; 83(1):43-52. PubMed ID: 30310970
[TBL] [Abstract][Full Text] [Related]
13. Meningeal hemangiopericytomas: a clinicopathological study with emphasis on MGMT (O(6) -methylguanine-DNA methyltransferase) promoter methylation status.
Kakkar A; Kumar A; Jha P; Goyal N; Mallick S; Sharma MC; Suri A; Singh M; Kale SS; Julka PK; Sarkar C; Suri V
Neuropathology; 2014 Aug; 34(4):333-42. PubMed ID: 24521400
[TBL] [Abstract][Full Text] [Related]
14. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
[TBL] [Abstract][Full Text] [Related]
15. O
Hiddinga BI; Pauwels P; Janssens A; van Meerbeeck JP
Lung Cancer; 2017 May; 107():91-99. PubMed ID: 27492578
[TBL] [Abstract][Full Text] [Related]
16. Expression and methylation status of MMR and MGMT in well-differentiated pancreatic neuroendocrine tumors and potential clinical applications.
Ban X; Mo S; Lu Z; Jia C; Shao H; Chang X; Mao X; Zhang Y; Pang J; Zhang Y; Yu S; Chen J
Endocrine; 2022 Sep; 77(3):538-545. PubMed ID: 35708896
[TBL] [Abstract][Full Text] [Related]
17. O6-methylguanine-DNA methyltransferase deficiency in developing brain: implications for brain tumorigenesis.
Bobola MS; Blank A; Berger MS; Silber JR
DNA Repair (Amst); 2007 Aug; 6(8):1127-33. PubMed ID: 17500046
[TBL] [Abstract][Full Text] [Related]
18. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Schwartz S; Szeto C; Tian Y; Cecchi F; Corallo S; Calegari MA; Di Bartolomeo M; Morano F; Raimondi A; Fucà G; Martinetti A; De Pascalis I; Martini M; Belfiore A; Milione M; Orlandi A; Barault L; Barone C; de Braud F; Di Nicolantonio F; Benz S; Hembrough T; Pietrantonio F
Eur J Cancer; 2019 Jan; 107():164-174. PubMed ID: 30579113
[TBL] [Abstract][Full Text] [Related]
19. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
Kulke MH; Hornick JL; Frauenhoffer C; Hooshmand S; Ryan DP; Enzinger PC; Meyerhardt JA; Clark JW; Stuart K; Fuchs CS; Redston MS
Clin Cancer Res; 2009 Jan; 15(1):338-45. PubMed ID: 19118063
[TBL] [Abstract][Full Text] [Related]
20. O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications.
Kang SH; Park KJ; Kim CY; Yu MO; Park CK; Park SH; Chung YG
J Neurooncol; 2011 Feb; 101(3):477-86. PubMed ID: 20556478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]